VSTM Stock — Verastem Inc

Verastem Inc (VSTM)

Updated October 16, 2026.

VSTM is a Stock. Total return is -93.5% over the past 14.7 years, 740.6 points behind SPY at 647.1%.

Verastem is a development-stage biopharmaceutical company focused on discovering and commercializing cancer treatments. Its pipeline includes Avutometinib, an oral RAF/MEK inhibitor targeting the RAS/MAPK signaling pathway, and Defactinib, an oral FAK inhibitor, with multiple clinical trials underway for various solid tumors and ovarian cancer. The company does not currently distribute to shareholders, making it oriented toward investors seeking capital appreciation rather than income.

VSTM performance versus SPY

Price and return data through 2026-10-16.

Total return is -93.5% over the past 14.7 years, 740.6 points behind SPY at 647.1%. Over the past year its total return — price change plus distributions reinvested — is -9.0%. Its deepest 1-year drawdown was 67.6%.

VSTM key facts

Asset type

Stock

Asset class

Equity

Inception date

01/27/2012

Distribution frequency

None

Last close

$8.65 (as of 2026-10-16)

Market cap

$783,373,765

Average volume

6087645.0

Beta

0.387

Payout ratio

0.0%

EPS

$-2.45

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

VSTM risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 67.6%.

Who may consider VSTM — and who may not

It is a weaker fit for investors who need monthly cash flow (VSTM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on VSTM

• All tickers starting with V

Tagged: Healthcare.

Frequently asked questions